Lymphomas
This session reviews current principles and data supporting the utilization of radiation therapy for patients with hematologic malignancies. We explore current treatment paradigms as well as modern radiation treatment techniques that are utilized in this patient population. We examine the indications for cellular therapies and how radiation therapy can serve as a therapeutic partner for the treatment of refractory disease.
Target Audience
The meeting is designed to meet the interests of practicing radiation oncologists, radiation oncology residents, medical and clinical physicists, radiation therapists, radiation dosimetrists, nurses and all other health professionals involved in the field of radiation oncology.
Learning Objectives
Upon completion of this activity, participants should be able to do the following:
- Understand the indications for consolidative radiation therapy for patients with early stage Hodgkin lymphoma and Diffuse large B-cell lymphoma.
- Have knowledge of targeted and cellular therapies used currently for patients with hematologic malignancies and how radiation therapy can serve as a therapeutic partner in several settings.
- Understand current treatment approaches for indolent B-cell lymphoma.
Planning Committee Disclosures
The person(s) above served as the developer(s) of this activity. Additionally, ASTRO Education Committee had control over the content of this activity.
All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Available Credit
- 1.25 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.